Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Bioactive peptides : applications for improving nutrition and health / / Richard Owusu-Apenten
| Bioactive peptides : applications for improving nutrition and health / / Richard Owusu-Apenten |
| Autore | Owusu-Apenten R. K. |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, , 2010 |
| Descrizione fisica | 1 online resource (416 p.) |
| Disciplina | 572/.65 |
| Soggetto topico |
Peptide drugs
Dietary supplements Proteins - Metabolism Proteins in human nutrition Appetite stimulants |
| Soggetto genere / forma | Electronic books. |
| ISBN |
0-429-13297-2
1-4398-1363-9 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Front cover; Contents; Preface; Acknowledgments; Author; Chapter 1: Nutrition and the HostResponse to Infectionand Injury; Chapter 2: Bioactive Peptidesfor Nutrition and Health; Chapter 3: Dietary ProteinRequirements for Health; Chapter 4: Protein Turnoverand Economics within the Body; Chapter 5: Major Processes forMuscle Gain and Loss; Chapter 6: Inflammation and InnateImmune Response; Chapter 7: Infection and Sepsis; Chapter 8: Anabolic Dysfunction; Chapter 9: Bioactive Peptidesfor Alleviating Illness Anorexia; Index; Back cover |
| Record Nr. | UNINA-9910459266003321 |
Owusu-Apenten R. K.
|
||
| Boca Raton : , : CRC Press, , 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bioactive peptides : applications for improving nutrition and health / / Richard Owusu-Apenten
| Bioactive peptides : applications for improving nutrition and health / / Richard Owusu-Apenten |
| Autore | Owusu-Apenten R. K. |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, , 2010 |
| Descrizione fisica | 1 online resource (416 p.) |
| Disciplina | 572/.65 |
| Soggetto topico |
Peptide drugs
Dietary supplements Proteins - Metabolism Proteins in human nutrition Appetite stimulants |
| ISBN |
0-429-13297-2
1-4398-1363-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Front cover; Contents; Preface; Acknowledgments; Author; Chapter 1: Nutrition and the HostResponse to Infectionand Injury; Chapter 2: Bioactive Peptidesfor Nutrition and Health; Chapter 3: Dietary ProteinRequirements for Health; Chapter 4: Protein Turnoverand Economics within the Body; Chapter 5: Major Processes forMuscle Gain and Loss; Chapter 6: Inflammation and InnateImmune Response; Chapter 7: Infection and Sepsis; Chapter 8: Anabolic Dysfunction; Chapter 9: Bioactive Peptidesfor Alleviating Illness Anorexia; Index; Back cover |
| Record Nr. | UNINA-9910784904303321 |
|
Owusu-Apenten R. K.
|
||
| Boca Raton : , : CRC Press, , 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bioactive peptides : applications for improving nutrition and health / / Richard Owusu-Apenten
| Bioactive peptides : applications for improving nutrition and health / / Richard Owusu-Apenten |
| Autore | Owusu-Apenten R. K. |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, , 2010 |
| Descrizione fisica | 1 online resource (416 p.) |
| Disciplina | 572/.65 |
| Soggetto topico |
Peptide drugs
Dietary supplements Proteins - Metabolism Proteins in human nutrition Appetite stimulants |
| ISBN |
0-429-13297-2
1-4398-1363-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Front cover; Contents; Preface; Acknowledgments; Author; Chapter 1: Nutrition and the HostResponse to Infectionand Injury; Chapter 2: Bioactive Peptidesfor Nutrition and Health; Chapter 3: Dietary ProteinRequirements for Health; Chapter 4: Protein Turnoverand Economics within the Body; Chapter 5: Major Processes forMuscle Gain and Loss; Chapter 6: Inflammation and InnateImmune Response; Chapter 7: Infection and Sepsis; Chapter 8: Anabolic Dysfunction; Chapter 9: Bioactive Peptidesfor Alleviating Illness Anorexia; Index; Back cover |
| Record Nr. | UNINA-9910799963903321 |
|
Owusu-Apenten R. K.
|
||
| Boca Raton : , : CRC Press, , 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Peptide and protein vaccines / / edited by Rossen Donev
| Peptide and protein vaccines / / edited by Rossen Donev |
| Pubbl/distr/stampa | Amsterdam, [Netherlands] : , : Academic Press, , 2015 |
| Descrizione fisica | 1 online resource (192 p.) |
| Disciplina | 572.65 |
| Collana | Advances in Protein Chemistry and Structural Biology |
| Soggetto topico |
Peptides - Therapeutic use
Proteins - Therapeutic use Peptide drugs |
| Soggetto genere / forma | Electronic books. |
| ISBN |
0-12-802869-6
0-12-802827-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Peptide and Protein Vaccines; Copyright; Contents; Contributors; Preface; References; Chapter 1: Peptide Immunotherapy in Vaccine Development: From Epitope to Adjuvant; 1. Introduction; 2. Cancer Vaccine; 3. Allergy Vaccine; 4. Alzheimerś Disease Vaccine; 5. Adjuvant and Delivery; 6. Perspectives and Conclusions; References; Chapter 2: The Use of Liposomes to Shape Epitope Structure and Modulate Immunogenic Responses of Peptide Vaccines Against...; 1. Introduction; 2. MPER: ASite of Vulnerability on HIV-1 Env and a Linear Epitope; 3. Structural Organization of MPER
3.1. Hydrophobicity Distribution3.2. MPER Peptide Structure; 4. Lipid Vesicles: Adjuvants and Devices to Shape MPER Structure; 4.1. Liposomes as Adjuvants; 4.2. The Lipid Bilayer as an MPER Scaffold; 5. Immunogenicity Studies of MPER-Derived Peptides in Liposomes; References; Chapter 3: Recombinant Lipoproteins as Novel Vaccines with Intrinsic Adjuvant; 1. Introduction; 2. Establishment of High Expression Recombinant Lipoprotein System; 3. The Lipid Structure of Lipoprotein; 4. Recombinant Lipoprotein with Intrinsic Adjuvant Properties 5. To Engineer Chimeric Lipoproteins with Intrinsic Adjuvant for Novel Vaccine Development6. Recombinant Chimeric Lipoproteins Can Activate BMDCs; 7. A Robustness Up- and Downstream Processes for Lipoprotein Production; 8. Recombinant Lipoprotein-Based Subunit Vaccine Induces High Titers of Neutralizing Antibody and Longer Memory Immune Re...; 9. Recombinant Lipidated Human Papillomavirus E7 Induces Cellular Immune Responses and Protective Immunity Against Cervic...; 10. Conclusion; Acknowledgment; References Chapter 4: Perspective of Peptide Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers1. Introduction; 2. Licensed Adjuvants; 3. CpG-DNA: Adjuvant; 4. Phosphodiester Bond CpG-DNA; 5. Liposomes: Adjuvants; 6. Adjuvants for Peptide Vaccine; 7. Peptide Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers; 7.1. Antibody Production with Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers; 7.2. Prevention of Influenza A Virus Infection; 7.3. Prevention of Respiratory Syncytial Virus Infection 7.4. Cancer Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers8. Perspectives; Acknowledgments; References; Chapter 5: Chemical Platforms for Peptide Vaccine Constructs; 1. Introduction; 2. Multiple Antigenic Peptide System Using a PolyLys Core: ABoon to Synthetic Peptide Vaccines; 3. Synthetic Antigen Carrier Bearing N-(S-acetylmercaptoacetyl)-Glutamyl Residues; 4. Thioester as a Replacement for Natural Peptide Bond (Chemical Ligation): Construction of Proteins; 5. Synthetic Peptide Dendrimer with Thiazolidinyl Pendant 6. Oxime Chemistry for Synthetic Peptide-Based Vaccines |
| Record Nr. | UNINA-9910460999503321 |
| Amsterdam, [Netherlands] : , : Academic Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Peptide and protein vaccines / / edited by Rossen Donev
| Peptide and protein vaccines / / edited by Rossen Donev |
| Pubbl/distr/stampa | Amsterdam, [Netherlands] : , : Academic Press, , 2015 |
| Descrizione fisica | 1 online resource (192 p.) |
| Disciplina | 572.65 |
| Collana | Advances in Protein Chemistry and Structural Biology |
| Soggetto topico |
Peptides - Therapeutic use
Proteins - Therapeutic use Peptide drugs |
| ISBN |
0-12-802869-6
0-12-802827-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Peptide and Protein Vaccines; Copyright; Contents; Contributors; Preface; References; Chapter 1: Peptide Immunotherapy in Vaccine Development: From Epitope to Adjuvant; 1. Introduction; 2. Cancer Vaccine; 3. Allergy Vaccine; 4. Alzheimerś Disease Vaccine; 5. Adjuvant and Delivery; 6. Perspectives and Conclusions; References; Chapter 2: The Use of Liposomes to Shape Epitope Structure and Modulate Immunogenic Responses of Peptide Vaccines Against...; 1. Introduction; 2. MPER: ASite of Vulnerability on HIV-1 Env and a Linear Epitope; 3. Structural Organization of MPER
3.1. Hydrophobicity Distribution3.2. MPER Peptide Structure; 4. Lipid Vesicles: Adjuvants and Devices to Shape MPER Structure; 4.1. Liposomes as Adjuvants; 4.2. The Lipid Bilayer as an MPER Scaffold; 5. Immunogenicity Studies of MPER-Derived Peptides in Liposomes; References; Chapter 3: Recombinant Lipoproteins as Novel Vaccines with Intrinsic Adjuvant; 1. Introduction; 2. Establishment of High Expression Recombinant Lipoprotein System; 3. The Lipid Structure of Lipoprotein; 4. Recombinant Lipoprotein with Intrinsic Adjuvant Properties 5. To Engineer Chimeric Lipoproteins with Intrinsic Adjuvant for Novel Vaccine Development6. Recombinant Chimeric Lipoproteins Can Activate BMDCs; 7. A Robustness Up- and Downstream Processes for Lipoprotein Production; 8. Recombinant Lipoprotein-Based Subunit Vaccine Induces High Titers of Neutralizing Antibody and Longer Memory Immune Re...; 9. Recombinant Lipidated Human Papillomavirus E7 Induces Cellular Immune Responses and Protective Immunity Against Cervic...; 10. Conclusion; Acknowledgment; References Chapter 4: Perspective of Peptide Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers1. Introduction; 2. Licensed Adjuvants; 3. CpG-DNA: Adjuvant; 4. Phosphodiester Bond CpG-DNA; 5. Liposomes: Adjuvants; 6. Adjuvants for Peptide Vaccine; 7. Peptide Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers; 7.1. Antibody Production with Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers; 7.2. Prevention of Influenza A Virus Infection; 7.3. Prevention of Respiratory Syncytial Virus Infection 7.4. Cancer Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers8. Perspectives; Acknowledgments; References; Chapter 5: Chemical Platforms for Peptide Vaccine Constructs; 1. Introduction; 2. Multiple Antigenic Peptide System Using a PolyLys Core: ABoon to Synthetic Peptide Vaccines; 3. Synthetic Antigen Carrier Bearing N-(S-acetylmercaptoacetyl)-Glutamyl Residues; 4. Thioester as a Replacement for Natural Peptide Bond (Chemical Ligation): Construction of Proteins; 5. Synthetic Peptide Dendrimer with Thiazolidinyl Pendant 6. Oxime Chemistry for Synthetic Peptide-Based Vaccines |
| Record Nr. | UNINA-9910797252503321 |
| Amsterdam, [Netherlands] : , : Academic Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Peptide and protein vaccines / / edited by Rossen Donev
| Peptide and protein vaccines / / edited by Rossen Donev |
| Pubbl/distr/stampa | Amsterdam, [Netherlands] : , : Academic Press, , 2015 |
| Descrizione fisica | 1 online resource (192 p.) |
| Disciplina | 572.65 |
| Collana | Advances in Protein Chemistry and Structural Biology |
| Soggetto topico |
Peptides - Therapeutic use
Proteins - Therapeutic use Peptide drugs |
| ISBN |
0-12-802869-6
0-12-802827-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Peptide and Protein Vaccines; Copyright; Contents; Contributors; Preface; References; Chapter 1: Peptide Immunotherapy in Vaccine Development: From Epitope to Adjuvant; 1. Introduction; 2. Cancer Vaccine; 3. Allergy Vaccine; 4. Alzheimerś Disease Vaccine; 5. Adjuvant and Delivery; 6. Perspectives and Conclusions; References; Chapter 2: The Use of Liposomes to Shape Epitope Structure and Modulate Immunogenic Responses of Peptide Vaccines Against...; 1. Introduction; 2. MPER: ASite of Vulnerability on HIV-1 Env and a Linear Epitope; 3. Structural Organization of MPER
3.1. Hydrophobicity Distribution3.2. MPER Peptide Structure; 4. Lipid Vesicles: Adjuvants and Devices to Shape MPER Structure; 4.1. Liposomes as Adjuvants; 4.2. The Lipid Bilayer as an MPER Scaffold; 5. Immunogenicity Studies of MPER-Derived Peptides in Liposomes; References; Chapter 3: Recombinant Lipoproteins as Novel Vaccines with Intrinsic Adjuvant; 1. Introduction; 2. Establishment of High Expression Recombinant Lipoprotein System; 3. The Lipid Structure of Lipoprotein; 4. Recombinant Lipoprotein with Intrinsic Adjuvant Properties 5. To Engineer Chimeric Lipoproteins with Intrinsic Adjuvant for Novel Vaccine Development6. Recombinant Chimeric Lipoproteins Can Activate BMDCs; 7. A Robustness Up- and Downstream Processes for Lipoprotein Production; 8. Recombinant Lipoprotein-Based Subunit Vaccine Induces High Titers of Neutralizing Antibody and Longer Memory Immune Re...; 9. Recombinant Lipidated Human Papillomavirus E7 Induces Cellular Immune Responses and Protective Immunity Against Cervic...; 10. Conclusion; Acknowledgment; References Chapter 4: Perspective of Peptide Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers1. Introduction; 2. Licensed Adjuvants; 3. CpG-DNA: Adjuvant; 4. Phosphodiester Bond CpG-DNA; 5. Liposomes: Adjuvants; 6. Adjuvants for Peptide Vaccine; 7. Peptide Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers; 7.1. Antibody Production with Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers; 7.2. Prevention of Influenza A Virus Infection; 7.3. Prevention of Respiratory Syncytial Virus Infection 7.4. Cancer Vaccine Composed of Epitope Peptide, CpG-DNA, and Liposome Complex Without Carriers8. Perspectives; Acknowledgments; References; Chapter 5: Chemical Platforms for Peptide Vaccine Constructs; 1. Introduction; 2. Multiple Antigenic Peptide System Using a PolyLys Core: ABoon to Synthetic Peptide Vaccines; 3. Synthetic Antigen Carrier Bearing N-(S-acetylmercaptoacetyl)-Glutamyl Residues; 4. Thioester as a Replacement for Natural Peptide Bond (Chemical Ligation): Construction of Proteins; 5. Synthetic Peptide Dendrimer with Thiazolidinyl Pendant 6. Oxime Chemistry for Synthetic Peptide-Based Vaccines |
| Record Nr. | UNINA-9910818574903321 |
| Amsterdam, [Netherlands] : , : Academic Press, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Peptide chemistry and drug design / / edited by Ben M. Dunn
| Peptide chemistry and drug design / / edited by Ben M. Dunn |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2015 |
| Descrizione fisica | 1 online resource (337 pages) : illustrations (some color), charts |
| Disciplina | 615.1/9 |
| Soggetto topico |
Drugs - Design
Peptide drugs Peptides - Synthesis |
| ISBN |
1-118-99641-0
1-118-99530-9 1-118-99528-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910140478603321 |
| Hoboken, New Jersey : , : Wiley, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Peptide chemistry and drug design / / edited by Ben M. Dunn
| Peptide chemistry and drug design / / edited by Ben M. Dunn |
| Pubbl/distr/stampa | Hoboken, New Jersey : , : Wiley, , 2015 |
| Descrizione fisica | 1 online resource (337 pages) : illustrations (some color), charts |
| Disciplina | 615.1/9 |
| Soggetto topico |
Drugs - Design
Peptide drugs Peptides - Synthesis |
| ISBN |
1-118-99641-0
1-118-99530-9 1-118-99528-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910828915703321 |
| Hoboken, New Jersey : , : Wiley, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Peptide drug discovery and development [[electronic resource] ] : translational research in academia and industry / / edited by Miguel Castanho and Nuno C. Santos
| Peptide drug discovery and development [[electronic resource] ] : translational research in academia and industry / / edited by Miguel Castanho and Nuno C. Santos |
| Pubbl/distr/stampa | Weinheim, Germany, : Wiley-VCH, 2011 |
| Descrizione fisica | 1 online resource (392 p.) |
| Disciplina |
572.65
615.19 |
| Altri autori (Persone) |
CastanhoMiguel
SantosNuno C |
| Soggetto topico |
Peptide drugs
Drugs - Design Pharmacology |
| ISBN |
3-527-63674-9
1-283-30251-9 9786613302519 3-527-63673-0 3-527-63675-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Peptide Drug Discovery and Development: Translational Research in Academia and Industry; Contents; Preface; List of Contributors; Part I: The Academia - Market Bouncing of Peptide Drugs - Challenges and Strategies in Translational Research with Peptide Drugs; 1: Peptides as Leads for Drug Discovery; 1.1: Introduction; 1.2: Overview of Process for Transforming Peptides to Peptidomimetics; 1.3: HCMV Protease; 1.3.1: HCMV Protease: Identification and Characterization of Antiviral Inhibitors Targeting the Serine Protease Domain of the Human Cytomegalovirus (HCMV Protease)
1.3.2: Mapping Essential Elements of the Substrate Peptides and Determining Structures of Ligands Bound to HCMV1.3.3: Improving Peptide Activity to Allow SAR Studies; 1.3.4: Elucidation of the Binding Mode of the Optimized Peptidyl Segment; 1.3.5: Ligand Adaptations upon Binding; 1.3.6: Strategic Summary for HCMV Peptide Mimic Design Process; 1.4: HCV Protease; 1.4.1: HCV Protease as an Antiviral Target; 1.4.2: NS3 Serine Protease Possesses a Chymotrypsin-Like Fold; 1.4.3: Discovery of the Peptide DDIVPC as an Inhibitor of NS3 Protease 1.4.4: ''Sensemaking'' and Knowledge Building: Mapping of the Critical Binding Residues of the Peptide and Creation of an Inhibitor-Protease Model1.4.5: Knowledge Building: Monitoring Ligand Flexibility in the Free-State and Changes Upon Binding - P3 Rigidification; 1.4.6: N-Terminal Truncation and Improved P1, P2 and P5 Substituents; 1.4.7: Macrocyclization: Linking the Flexible P1 Side-Chain to P3; 1.4.8: HCV Protease Inhibitor BI00201335; 1.5: Herpes Simplex Virus; 1.5.1: Herpes Simplex Virus-Encoded Ribonucleotide Reductase Inhibitors; 1.6: Renin 1.6.1: Aspartyl Protease Renin as a Target1.7: HIV; 1.7.1: HIV Protease Inhibitors; 1.8: Conclusions; 2: Marketing Antimicrobial Peptides: A Critical Academic Point of View; 2.1: Introduction; 2.2: Basic Research: Antimicrobial Peptides; 2.3: Patents; 2.4: Potential Applications of AMPs; 2.5: Technology Transfer: Valorization, Licensing, or Spin-Off Creation; 2.6: Spin-Off Creation: An Academic Point of View; 3: Oral Peptide Drug Delivery: Strategies to Overcome Challenges; 3.1: Introduction; 3.2: Challenges Associated with Oral Peptide Delivery 3.2.1: Transport Pathways Across the Intestinal Epithelium3.2.2: Unfavorable Physicochemical Properties of Peptide Drugs; 3.2.2.1: Molecular Size, Hydrophilicity, and Physical Stability; 3.2.3: Physical Barriers of the Gastrointestinal Tract; 3.2.3.1: Transcellular Pathway; 3.2.3.2: Paracellular Pathway; 3.2.4: Biochemical Barriers of the Gastrointestinal Tract; 3.2.4.1: Luminal Enzymes; 3.2.4.2: Brush Border Membrane Bound Enzymes and Intracellular Enzymes; 3.2.5: Efflux Transport Systems; 3.2.6: Gastrointestinal Transit Time and Site-Specific Absorption 3.3: Strategies to Overcome the Barriers of the Gastrointestinal Tract |
| Record Nr. | UNINA-9910139579303321 |
| Weinheim, Germany, : Wiley-VCH, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Peptide drug discovery and development : translational research in academia and industry / / edited by Miguel Castanho and Nuno C. Santos
| Peptide drug discovery and development : translational research in academia and industry / / edited by Miguel Castanho and Nuno C. Santos |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Weinheim, Germany, : Wiley-VCH, 2011 |
| Descrizione fisica | 1 online resource (xix, 370 pages) : illustrations |
| Disciplina |
572.65
615.19 |
| Altri autori (Persone) |
CastanhoMiguel
SantosNuno C |
| Soggetto topico |
Peptide drugs
Drugs - Design Pharmacology |
| ISBN |
3-527-63674-9
1-283-30251-9 9786613302519 3-527-63673-0 3-527-63675-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Peptide Drug Discovery and Development: Translational Research in Academia and Industry; Contents; Preface; List of Contributors; Part I: The Academia - Market Bouncing of Peptide Drugs - Challenges and Strategies in Translational Research with Peptide Drugs; 1: Peptides as Leads for Drug Discovery; 1.1: Introduction; 1.2: Overview of Process for Transforming Peptides to Peptidomimetics; 1.3: HCMV Protease; 1.3.1: HCMV Protease: Identification and Characterization of Antiviral Inhibitors Targeting the Serine Protease Domain of the Human Cytomegalovirus (HCMV Protease)
1.3.2: Mapping Essential Elements of the Substrate Peptides and Determining Structures of Ligands Bound to HCMV1.3.3: Improving Peptide Activity to Allow SAR Studies; 1.3.4: Elucidation of the Binding Mode of the Optimized Peptidyl Segment; 1.3.5: Ligand Adaptations upon Binding; 1.3.6: Strategic Summary for HCMV Peptide Mimic Design Process; 1.4: HCV Protease; 1.4.1: HCV Protease as an Antiviral Target; 1.4.2: NS3 Serine Protease Possesses a Chymotrypsin-Like Fold; 1.4.3: Discovery of the Peptide DDIVPC as an Inhibitor of NS3 Protease 1.4.4: ''Sensemaking'' and Knowledge Building: Mapping of the Critical Binding Residues of the Peptide and Creation of an Inhibitor-Protease Model1.4.5: Knowledge Building: Monitoring Ligand Flexibility in the Free-State and Changes Upon Binding - P3 Rigidification; 1.4.6: N-Terminal Truncation and Improved P1, P2 and P5 Substituents; 1.4.7: Macrocyclization: Linking the Flexible P1 Side-Chain to P3; 1.4.8: HCV Protease Inhibitor BI00201335; 1.5: Herpes Simplex Virus; 1.5.1: Herpes Simplex Virus-Encoded Ribonucleotide Reductase Inhibitors; 1.6: Renin 1.6.1: Aspartyl Protease Renin as a Target1.7: HIV; 1.7.1: HIV Protease Inhibitors; 1.8: Conclusions; 2: Marketing Antimicrobial Peptides: A Critical Academic Point of View; 2.1: Introduction; 2.2: Basic Research: Antimicrobial Peptides; 2.3: Patents; 2.4: Potential Applications of AMPs; 2.5: Technology Transfer: Valorization, Licensing, or Spin-Off Creation; 2.6: Spin-Off Creation: An Academic Point of View; 3: Oral Peptide Drug Delivery: Strategies to Overcome Challenges; 3.1: Introduction; 3.2: Challenges Associated with Oral Peptide Delivery 3.2.1: Transport Pathways Across the Intestinal Epithelium3.2.2: Unfavorable Physicochemical Properties of Peptide Drugs; 3.2.2.1: Molecular Size, Hydrophilicity, and Physical Stability; 3.2.3: Physical Barriers of the Gastrointestinal Tract; 3.2.3.1: Transcellular Pathway; 3.2.3.2: Paracellular Pathway; 3.2.4: Biochemical Barriers of the Gastrointestinal Tract; 3.2.4.1: Luminal Enzymes; 3.2.4.2: Brush Border Membrane Bound Enzymes and Intracellular Enzymes; 3.2.5: Efflux Transport Systems; 3.2.6: Gastrointestinal Transit Time and Site-Specific Absorption; 3.3: Strategies to Overcome the Barriers of the Gastrointestinal Tract |
| Record Nr. | UNINA-9910829074503321 |
| Weinheim, Germany, : Wiley-VCH, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
